Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://ncbi.nlm.nih.gov/pubmed/30545923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados